Briefing Information for the December 11, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee
Disclaimer: Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
Amylin Pharmaceuticals, LLC
Disclaimer: The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.